Welcome to our dedicated page for LENSAR SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENSAR, Inc. filings document operating results and material events for a commercial-stage medical device company focused on robotic laser systems for cataract procedures. Form 8-K reports furnish quarterly and annual earnings releases, including disclosures on ALLY system activity, installed-base trends, and recurring revenue components such as procedure, lease, and service revenue.
The company’s filings also record capital and governance matters, including common stock listed on Nasdaq under LNSR, officer transition disclosures, and material agreements such as the Priority Credit Line Agreement. Amendments to material-event reports provide additional detail on credit-line terms, collateral arrangements, interest-rate mechanics, and default provisions.
LENSAR, Inc. filed its proxy for the 2025 annual meeting, to be held virtually on December 18, 2025 at 11:00 a.m. ET via www.virtualshareholdermeeting.com/LNSR2025. Holders of record as of October 24, 2025 may vote.
Stockholders will vote on: (1) electing Class II directors Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner to terms ending at the 2028 annual meeting; and (2) ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for 2025. The Board recommends voting FOR all proposals.
As of the record date, there were 11,944,546 shares of common stock and 20,000 shares of Series A Convertible Preferred Stock outstanding and entitled to vote together as a class. Proposal 1 uses plurality voting; Proposal 2 requires a majority of votes cast. Audit fees billed by PwC were $1,086,881 for 2024. The meeting, as contemplated, will occur only if the Merger with Alcon Research, LLC has not been completed by that date.
LENSAR, Inc. announced its 2025 annual meeting of stockholders is scheduled for December 18, 2025 and will be held virtually. Stockholders of record as of the close of business on October 24, 2025 may vote.
The meeting will only occur if the proposed merger with Alcon Research, LLC is not completed before that date. If the merger closes earlier, the company will become a wholly owned subsidiary and the meeting, director nominations, and any stockholder proposals will not be considered.
Deadlines: to be included in the proxy under Rule 14a-8, proposals must be received by October 31, 2025. For other bylaw proposals or director nominations, written notice is due by October 31, 2025. Universal proxy Rule 14a-19 notices are also due by October 31, 2025.
LENSAR (NASDAQ:LNSR) filed additional proxy materials for its pending $14 per-share cash merger with Alcon. The supplement answers shareholder demand letters claiming the May 19 definitive proxy omitted material facts, potentially violating Sections 14(a)/20(a). To pre-empt litigation, LENSAR adds disclosures while denying wrongdoing.
Key additions:
- Confirms no discussions of post-merger employment or equity for executives during Feb 21-26 2025 talks.
- Updates Wells Fargo Securities comps: mean EV/2025E revenue 3.9×, median 2.8×; LENSAR traded at 5.2×.
- WFS selects 4.00-5.25× 2025E and 3.00-4.00× 2026E revenue multiples, implying $12.27–$16.51 per share versus $14.00 cash offer and $16.03 discounted amount.
- Expanded precedent-transaction table (4.0×–6.5× LTM revenue).
The board’s recommendation and the July 2 2025 special-meeting timetable are unchanged.